14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
AVDL vs HCM
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs HCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
AVDL Overall Winner
6-Pillar Tally: AVDL 4 – 1 HCM (1 Tie)
Matrix Metrics: AVDL 7 – 3 HCM
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin).
AVDL
NASDAQ
Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
Market Cap
$2.1B
TTM Revenue
$249M
Forward P/E
28.8x
Beta / 30D Vol
0.14β · 2% Vol
Unified Composite Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
HCM
NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
Market Cap
$2.3B
TTM Revenue
$549M
Forward P/E
N/M
Beta / 30D Vol
0.64β · 45% Vol
Unified Composite Score
38.1 / 100
SELL
Tech 31.0
Fund 44.0
Flow 50.0
Mom 56.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11
6-Pillar Scorecard Institutional Category Breakdown (AVDL 4 – 1 HCM)
Columns: Metric · AVDL · HCM
1. Valuation Multiples
AVDL
Forward P/E
28.8x
N/M
Trailing P/E
16.8x
134.0x
PEG Ratio
0.07x
N/M
EV / Revenue
8.5x
4.2x
2. Growth & Scale
AVDL
Revenue Growth (YoY)
+54.9%
+0.2%
Earnings Growth (YoY)
+0.0%
-96.5%
TTM Revenue (USD)
$249M
$549M
Market Cap
$2.1B
$2.3B
3. Profitability & Quality
AVDL
Gross Margin
94.9%
13.3%
Operating Margin
2.5%
-6.3%
Net Profit Margin
-0.1%
3.3%
Return on Equity (ROE)
-0.3%
1.5%
4. Balance Sheet & Cash Flow
AVDL
Cash Generation (TTM)
$2.7M EBITDA
-$21M EBITDA
Cash Flow Margin
1.1% EBITDA Mgn
-3.7% EBITDA Mgn
Net Cash / Leverage
$1.01 Book/Sh · -0.3% ROE
$7.25 Book/Sh · 1.5% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
2.4% (<1st %ile)
82.7% (73rd %ile)
Put/Call OI Skew
N/A
Thin ADR Chain
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
HCM
OpEx & R&D Intensity
N/A
19.6% of Rev ($108M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AVDL (7) vs HCM (3)
Institutional Metric
AVDL
HCM
Criterion
Row Edge
Market Capitalization
Scale
$2.1B
$2.3B
Larger Scale
HCM
Trailing P/E Ratio
Valuation
16.8x
134.0x
Lower Multiple
AVDL
Forward P/E Ratio
Valuation
28.8x
N/M
Lower Multiple
AVDL
Revenue Growth (YoY)
Growth
+54.9%
+0.2%
Higher Growth
AVDL
Operating Margin (TTM)
Profitability
2.5%
-6.3%
Higher Margin
AVDL
Net Profit Margin
Profitability
-0.1%
3.3%
Higher Margin
HCM
Return on Equity (ROE)
Capital Efficiency
-0.3%
1.5%
Higher ROE
HCM
52-Week Range Position
Momentum
89% ($6–$24)
53% ($10–$16)
Stronger Trend
AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol
0.64β · 45% Vol
Lower Realized Risk
AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY)
38.1 / 100 (SELL)
Higher Composite
AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M
$549M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9%
13.3%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev
N/M PEG · 4.2x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE)
-$21M EBITDA ($7.25 Book/Sh · 1.5% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
HCM +0.56 pp
AVDL:
+0.65%
·
HCM:
+1.21%
3M Horizon
HCM +8.74 pp
AVDL:
-5.67%
·
HCM:
+3.07%
6M Horizon
HCM +8.74 pp
AVDL:
-5.67%
·
HCM:
+3.07%
1Y Horizon
HCM +8.74 pp
AVDL:
-5.67%
·
HCM:
+3.07%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs HCM. Trailing 12-month operating profitability (AVDL 2.5% vs HCM -6.3%) and valuation multiples (AVDL 28.8x vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
AVDL ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $249M
Gross Margin 94.9%
Op. Margin 2.5%
ROE / Fwd P/E -0.3% · 28.8x
HCM ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $549M
Gross Margin 13.3%
Op. Margin -6.3%
ROE / Fwd P/E 1.5% · N/M
AVDL
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
2.4%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
HCM
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
82.7%
IV Percentile
73rd %ile
Put/Call OI Skew
Thin ADR Chain
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
AVDL Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
HCM Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment
19.6% of Rev ($108M)
90D Engineering Disclosures
0 Published
Investor FAQ AVDL vs HCM Key Questions & Quantitative Answers
Is AVDL or HCM a better stock to buy right now?
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin). Technically, AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure) and HCM sits in a Neutral phase (RSI 38.5, UNCLASSIFIED options structure).
Does AVDL or HCM have stronger revenue and earnings growth?
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.
Is AVDL or HCM cheaper on valuation?
AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus HCM (1.5% ROE) capital efficiency.
How is options market volatility positioned on AVDL vs HCM?
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk).
Avadel Pharmaceuticals plc Ordinary Share (AVDL) Research Suite
HUTCHMED (China) Limited American Depositary Shares (HCM) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.